Lyra Therapeutics, Inc.
LYRA
$0.0873
$0.00080.93%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 7.53% | 75.33% | -114.37% | -48.14% | 3.16% |
| Total Depreciation and Amortization | 287.18% | -73.10% | 6.62% | 60.00% | 225.00% |
| Total Amortization of Deferred Charges | -- | -100.00% | -- | -- | -- |
| Total Other Non-Cash Items | 53.39% | -95.67% | 1,947.84% | 211.93% | 2.34% |
| Change in Net Operating Assets | 59.92% | -303.15% | 297.15% | 68.77% | -459.10% |
| Cash from Operations | 30.03% | 18.81% | 11.02% | -17.82% | -35.03% |
| Capital Expenditure | 213.73% | 73.98% | 90.88% | -173.06% | -446.53% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 242.69% | -77.48% | 263.50% | 736.51% | 89.40% |
| Cash from Investing | 245.55% | -77.50% | 360.43% | 433.06% | 84.25% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -100.00% | -99.90% | -54.20% | 962,000.00% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 100.00% | 76.53% | 42.01% | 47.52% | 23.33% |
| Cash from Financing | 95.65% | 74.16% | -101.03% | -54.31% | 4,626.32% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 307.01% | -150.32% | 370.51% | -138.45% | 91.54% |